Arsenite Resistance in Leishmania and Possible Drug Targets
Parasitic infections are of enormous public health importance. Leishmaniasis is currently regarded as the second-most dreaded parasitic disease after malaria (WHO). Visceral leishmaniasis or kala-azar, caused by Leishmania donovani, is the most fatal form of leishmaniasis afflicting millions of people worldwide. No vaccination is available against leishmaniasis and fast spreading drug resistance in these parasitic organisms is posing a major medical threat. All these emphasize the need for new drugs and molecular targets along with reappraisal of existing therapeutics. Identification and characterization of cellular targets and answering the problem of drug resistance in Leishmania has always been the main thrust of protozoal research worldwide. Model drug resistance phenotypes against drugs, viz. arsenite (an antimony related metal ion, the first line of treatment against leishmaniasis), have been widely used to address and understand mechanism of drug resistance. The present discussion is an attempt to understand the different factors associated with arsenite resistance in Leishmania.
KeywordsVisceral Leishmaniasis Sodium Arsenite Leishmania Donovani Antimicrotubule Agent Protozoan Parasite Leishmania
Unable to display preview. Download preview PDF.
- 30.Lin YC, Hsu JY, Chiang SC et al. Distinct overexpression of cytosolic and mitochondrial tryparedoxin peroxidases results in preferential detoxification of different oxidants in arsenite-resistant Leishmania amazonensis with and without DNA amplification. Mol Biochem Parasitol 2005; 142:66–75.PubMedCrossRefGoogle Scholar
- 44.Jayanarayan KG, Dey CS. Altered tubulin dynamics, localization and post-translational modifications in sodium arsenite resistant Leishmania donovani in response to paclitaxel, trifluralin and a combination of both and induction of apoptosis-like cell death. Parasitology 2005; 131:215–230.PubMedCrossRefGoogle Scholar